Pulse Biosciences, Inc (NASDAQ:PLSE) Stock Has Average Target Price of $50.20

Pulse Biosciences, Inc (NASDAQ:PLSE) has received a consensus recommendation of “Moderate Buy” from the seven brokerages that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, five have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $53.20.

A number of brokerages have issued reports on PLSE. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pulse Biosciences in a research note on Friday, July 17th. Mizuho set a $45.00 target price on Pulse Biosciences in a research note on Monday, August 10th. Freedom Capital upgraded Pulse Biosciences to a “strong-buy” rating in a report on Wednesday, September 9th. Needham & Company LLC began coverage on Pulse Biosciences in a research report on Monday, August 17th. They issued a “buy” rating and a $58.00 price target for the company. Finally, Canaccord Genuity Group increased their price objective on shares of Pulse Biosciences from $43.00 to $58.00 and gave the company a “buy” rating in a research report on Tuesday.

Pulse Biosciences Stock Performance

Shares of PLSE opened at $49.98 on Tuesday. Pulse Biosciences has a fifty-two week low of $12.56 and a fifty-two week high of $58.90. The firm’s 50-day simple moving average is $48.59 and its two-hundred day simple moving average is $33.26. The stock has a market cap of $3.54 billion, a PE ratio of -42.36 and a beta of 1.57.

Pulse Biosciences (NASDAQ:PLSE) last released its earnings results on Thursday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.07). The business had revenue of $0.43 million for the quarter, compared to analysts’ expectations of $0.53 million. Pulse Biosciences had a negative net margin of 6,755.78% and a negative return on equity of 94.42%. Equities research analysts predict that Pulse Biosciences will post -1.29 EPS for the current year.

Insider Activity

In other news, COO Liane Teplitsky purchased 1,036 shares of the business’s stock in a transaction dated Wednesday, August 26th. The shares were purchased at an average price of $48.23 per share, for a total transaction of $49,966.28. Following the completion of the acquisition, the chief operating officer directly owned 1,036 shares in the company, valued at $49,966.28. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders have purchased a total of 4,095 shares of company stock valued at $199,931 in the last 90 days. Corporate insiders own 74.00% of the company’s stock.

Hedge Funds Weigh In On Pulse Biosciences

Hedge funds have recently added to or reduced their stakes in the company. Osterweis Capital Management Inc. purchased a new stake in shares of Pulse Biosciences during the 2nd quarter valued at about $28,000. Jupiter Topco LLC bought a new stake in Pulse Biosciences during the second quarter valued at approximately $241,000. GSA Capital Partners LLP purchased a new stake in Pulse Biosciences during the second quarter valued at approximately $290,000. Legal & General Group Plc bought a new position in Pulse Biosciences in the second quarter worth approximately $395,000. Finally, Cetera Investment Advisers purchased a new position in shares of Pulse Biosciences during the 1st quarter worth $387,000. 76.95% of the stock is currently owned by hedge funds and other institutional investors.

About Pulse Biosciences

Pulse Biosciences, Inc is a medical technology company developing bioelectric therapies based on its proprietary Nano-Pulse Stimulation (NPS) technology. The platform delivers short, nonthermal electrical pulses that temporarily affect cell membranes and are designed to selectively target unwanted cells while preserving surrounding tissue.

The company’s lead commercial product is the CellFX System, a dermatology platform designed to treat certain benign skin lesions and other dermatologic conditions using NPS technology.